Mode
Text Size
Log in / Sign up
Phase 3 N=321 Randomized Double-blind Treatment

Nefopam/Paracetamol Fixed Dose Combination in Acute Pain After Impacted Third Molar Extraction

Acute Pain

Enrolled (actual)
321
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcome: Primary: Ranked Endpoints : 1. Sum of Pain Intensity Differences at 6 Hours (SPID0-6h) — 8955.4; 8458.0; 5290.7 score on a scale — p=0.0031

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
nefopam hydrochloride 30mg / paracetamol 500mg X2 (Combination_product); Paracetamol 500 Mg Oral Tablet X2 (Drug); Nefopam HCl 30 MG Oral Tablet X2 (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Unither Pharmaceuticals, France
Primary completion
Oct 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Ranked Endpoints : 1. Sum of Pain Intensity Differences at 6 Hours (SPID0-6h)
8955.4; 8458.0; 5290.7 0.0031 sig
PRIMARY
Total Pain Relief at 6 Hours (TOTPAR0-6h)
610.6; 602.2; 461.4
PRIMARY
Proportion of Responder Patients
47; 43; 35
PRIMARY
The Patient's Global Impression of Change (PGIC) Questionnaire
11; 14; 11; 39; 29; 30
PRIMARY
The Onset of Pain Relief
76; 74; 58
SECONDARY
Total Pain Relief at 1 Hour (TOTPAR0-1h), 2 Hours (TOTPAR0-2h), 3 Hours (TOTPAR0-3h), and 4 Hours (TOTPAR0-4h)
60.2; 69.4; 49.7; 170.0; 183.0; 133.2
SECONDARY
Sum of Pain Intensity Differences at 1 Hour (SPID0-1h), 2 Hours (SPID0-2h), 3 Hours (SPID0-3h), and 4 Hours (SPID0-4h)
743.7; 809.5; 506.4; 2405.9; 2418.4; 1487.2
SECONDARY
The Pain Intensity Differences (PID) Assessment
-11.4; -14.8; -8.6; -20.1; -19.6; -12.7
SECONDARY
Proportion of Responder Patients.
44; 45; 34; 57; 54; 38
SECONDARY
Time to the Second Investigational Medicinal Product (IMP) Intake
438.5; 429.0; 387.0
SECONDARY
Participant Having Taken a Rescue Analgesic Treatment
19; 26; 35
SECONDARY
Sum of Pain Intensity Differences
23306.5; 22173.7; 19910.3; 48792.4; 44604.7; 42972.1
SECONDARY
Proportion of Patients Having Taken a Rescue Analgesic Treatment Throughout the Study.
19; 26; 35
SECONDARY
The Total Dose of Rescue Medication Taken.
7.1; 7.3; 6.0
SECONDARY
Mean Duration Under Rescue Medication Over the 5 Days.
57.9; 99.4; 61.9
SECONDARY
Number of Investigational Medicinal Product (IMP) Intakes
6.4; 5.8; 5.1
SECONDARY
Patient's Global Impression of Change (PGIC) Score
36; 39; 34; 40; 46; 40

Summary

This study aims to evaluate the analgesic efficacy of single and multiple doses of a new fixed dose combination of nefopam hydrochloride 30 mg and paracetamol 500mg taken orally in comparison to each single component.

Eligibility Criteria

Main Inclusion Criteria:

  • Male and female patient aged from 18 years up to 65 years,
  • Patient scheduled to undergo the surgical removal of at least one fully or partially impacted third mandibular molar requiring bone removal under short-acting local anaesthetic (mepivacaine or lidocaine) with or without vasoconstrictor,
  • Patient weighing > 50 kg,
  • Patient who has signed a written informed consent prior to any study-related procedures.

Additional inclusion criteria after surgery (randomization):

  • Patient experiencing moderate to severe pain within 4 hours after the dental extraction, defined by a baseline pain intensity Visual Analogic Scale (VAS) score ≥ 50 mm,
  • Third molar extraction(s) completed without any immediate complication, that in the opinion of the investigator, would interfere with the study conduct and/or assessments (e.g., suspected neurosensory complication, incomplete removal of tooth)

Main Exclusion Criteria:

  • Patient treated by analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) within 3 days preceding the day of randomization or within 5 times the elimination half-life whichever the longest,
  • Woman with positive results on a urine pregnancy test or breastfeeding woman or woman of childbearing potential without an effective contraception,
  • Patient with a history of convulsive disorders,
  • Patient taking mono-amine-oxidase (MAO) inhibitors (including but not limited to selegiline, isocarboxazid, tranylcypromine, phenelzine…),
  • Patient with an abnormal cardiac condition: medically significant disorders of cardiac rate and/or rhythm,
  • Patient with known anaemia,
  • Patient with known pulmonary disease,
  • Patient with known active gastric or duodenal ulcer or a history of recurrent gastrointestinal ulcer/bleeding,
  • Patient with known glaucoma,
  • Patients with a prostatic hyperplasia or urinary retention,
  • Patient with current or chronic history of liver disease, or known hepatic or biliary abnormalities,
  • Patient with a current or chronic history of severe renal impairment (glomerular filtration below 30 mL/min),
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04622735). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search